Strahlentherapie und Onkologie, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 26, 2024
Language: Английский
Nano-Micro Letters, Journal Year: 2025, Volume and Issue: 17(1)
Published: Feb. 21, 2025
The emerging messenger RNA (mRNA) nanomedicines have sprung up for disease treatment. Developing targeted mRNA has become a thrilling research hotspot in recent years, as they can be precisely delivered to specific organs or tissues enhance efficiency and avoid side effects. Herein, we give comprehensive review on the latest progress of with targeting functions. its carriers are first described detail. Then, mechanisms passive targeting, endogenous active outlined, focus various biological barriers that may encounter during vivo delivery. Next, emphasis is placed summarizing mRNA-based organ-targeting strategies. Lastly, advantages challenges clinical translation mentioned. This expected inspire researchers this field drive further development technology.
Language: Английский
Citations
1
BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)
Published: Feb. 7, 2025
Pleural Mesothelioma (PM) is a highly aggressive cancer, for which effective early detection remains challenge due to limited screening options and low sensitivity of biomarkers discovered so far. While extracellular vesicles (EVs) have emerged as promising candidates blood-based biomarkers, their role in PM has not been studied yet. In this study, we characterized the transcriptomic profile EVs secreted by primary cells explored potential biomarker source detection. We collected cell culture supernatant from early-passage cultures derived pleural effusion 4 patients. were isolated using Qiagen exoEasy Maxi kit. RNA isolation was done mirVana PARIS Finally, single-end sequencing with Illumina Novaseq 6000. identified range species expressed cells, including protein-coding (80%), long non-coding (13%), pseudogenes (4.5%), short (1.6%). detected subset genes associated previously epithelioid (32 genes) sarcomatoid molecular components (36 PM-EVs. To investigate whether these markers could serve blood, compared content PM-EVs cargo plasma healthy donors (publicly available data). Majority upregulated RNAs. Interestingly, 25 them marker genes. functional analysis revealed that PM-EV Epithelial-Mesenchymal transition, glycolysis, hypoxia. This first study characterize cultures, demonstrating Further investigation will provide new insights into disease biology therapeutic avenues.
Language: Английский
Citations
0
Journal of Cellular and Molecular Medicine, Journal Year: 2025, Volume and Issue: 29(5)
Published: March 1, 2025
Triple-negative breast cancer (TNBC) is a highly aggressive form of with poor prognosis and high mortality. The chemotherapeutic regimen remains the predominant treatment modality for TNBC in current clinical practice. However, chemotherapy resistance significantly complicates development an effective regimen. Furthermore, immunosuppressive microenvironment contributes to enhanced tumour aggressiveness. Consequently, understanding its mechanisms progression finding therapeutic interventions crucial. Recent evidence has identified extracellular vesicles (EVs) as key mediators cell-to-cell communication immune regulation. In view remarkable ability EVs transfer active molecules, such proteins nucleic acids, from parental recipient cells, they are regarded promising biomarker novel drug delivery system. this review, we provide overview how derived cells play role regulating progression. We also discuss potential regulation their application strategies markers TNBC. knowledge gained studying EV-mediated could lead targeted therapies improve patient outcomes.
Language: Английский
Citations
0
Strahlentherapie und Onkologie, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 26, 2024
Language: Английский
Citations
1